Citations

Mayo Clinic

Showing 10 of 108304 citations.

Heparin-Degrading Sulfatases in Hepatocellular Carcinoma: Roles in Pathogenesis and Therapy Targets
Lai, Jin-Ping, Thompson, James , Sandhu, Dalbir S. , Roberts, Lewis R. , Thompson, James R. , Roberts, Lewis R

Future Oncology | December 16, 2008 | Volume: 4 | Issue: 6 | Pages: 803-814

10.2217/14796694.4.6.803 | PMID 19086847 Get It

SYNERGISTIC WRIST DYNAMIC SPLINT FOR FLEXOR TENDON REPAIR
Chou, Pei-Hsi, Chou, You-Li, An, Kai‐Nan , Lin, Gau‐Tyan, Su, Fong‐Chin , Yang, C.S., HUANG, GWO-FENG

Biomedical Engineering: Applications, Basis and Communications | December 16, 2008 | Volume: 13 | Issue: 05 | Pages: 231-241

10.4015/s1016237201000297 Get It

Tendons are frequently injured by direct trauma. Tendon adhesions were a common sequel of tendon repair and are one of the most challenging problems in hand surgery. The concept of “controlled motion” gradually replaced “total immobilization” in the treatment of flexor tendon injuries and today represents a standard of care for all primary repaired flexor tendon injury. Use of controlled motion splints during the early stages of stages of tendon recovery in crease tendon gliding. However, how best to achieve passive motion and the effect of passive motion on tendon gliding have remained controversial subjects. Based on a series of recent experiments, the concept of “dynamic synergistic wrist motion splint” was established and evaluated. It was found that this synergistic wrist motion increases the tendon excursion due to eliminating the laxity and buckling of tendon in the regions between pulleys without introduce excessive amount of tension. The purpose of this study is to design and fabricate a dynamic splint based on this concept and define the nature coordinated motion between the wrist and finger joints due to the passive tension of the muscles in vivo. Parametric analysis will be conducted to achieve an optimum design with the consideration of anatomic constraints. Clinical trial of using such dynamic splint will be evaluated in the future.
Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Risedronate for the Prevention of Bone Loss in Premenopausal Women Undergoing Chemotherapy for Primary Breast Cancer
Hines, Stephanie L., Mincey, Betty A., Sloan, Jeff A. , Thomas, Sachdev , Chottiner, Elaine G., Loprinzi, Charles L. , Carlson, Mark D., Atherton, Pamela J., Salim, Muhammad , Perez, Edith A. , Atherton, Philip J. , Atherton, Pamela J., Atherton, Philip J.

Journal of Clinical Oncology | December 16, 2008 | Volume: 27 | Issue: 7 | Pages: 1047-1053

10.1200/jco.2008.19.1783 | PMID 19075260 Get It

Purpose Risedronate prevents bone loss in postmenopausal women. The purpose of this study was to determine whether risedronate prevents bone loss in premenopausal women undergoing chemotherapy for breast cancer. Patients and Methods Premenopausal women undergoing chemotherapy for breast cancer were treated with oral calcium 600 mg and vitamin D 400 U daily and randomly assigned to receive oral risedronate 35 mg weekly or placebo, with all these therapies beginning within a month of the start of chemotherapy. Most chemotherapy regimens included anthracyclines, taxanes, or cyclophosphamide. Bone mineral density (BMD) was measured at baseline and 1 year. The primary end point was the change in lumbar spine (LS) BMD from baseline to 1 year. Results A total of 216 women enrolled; 170 women provided BMD data at 1 year. There was no difference in the mean change or percent change in LS BMD between groups, with a loss of 4.3% in the risedronate arm and 5.4% for placebo at 1 year (P = .18). Loss of BMD at the femoral neck and total hip were also similar between treatment groups. Risedronate was well tolerated, with no significant differences in adverse events compared with placebo, except that arthralgias and chest pain were worse in those receiving the placebos. Conclusion Risedronate did not prevent bone loss in premenopausal women undergoing adjuvant chemotherapy for breast cancer.
Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate
Pederson, Larry, Ruan, Ming, Khosla, Sundeep , Oursler, Merry Jo, Westendorf, Jennifer J. , Khosla, Sundeep

Proceedings of the National Academy of Sciences | December 15, 2008 | Volume: 105 | Issue: 52 | Pages: 20764-20769

10.1073/pnas.0805133106 | PMID 19075223 Get It

Under most conditions, resorbed bone is nearly precisely replaced in location and amount by new bone. Thus, it has long been recognized that bone loss through osteoclast-mediated bone resorption and bone replacement through osteoblast-mediated bone formation are tightly coupled processes. Abundant data conclusively demonstrate that osteoblasts direct osteoclast differentiation. Key questions remain, however, as to how osteoblasts are recruited to the resorption site and how the amount of bone produced is so precisely controlled. We hypothesized that osteoclasts play a crucial role in the promotion of bone formation. We found that osteoclast conditioned medium stimulates human mesenchymal stem (hMS) cell migration and differentiation toward the osteoblast lineage as measured by mineralized nodule formation in vitro. We identified candidate osteoclast-derived coupling factors using the Affymetrix microarray. We observed significant induction of sphingosine kinase 1 (SPHK1), which catalyzes the phosphorylation of sphingosine to form sphingosine 1-phosphate (S1P), in mature multinucleated osteoclasts as compared with preosteoclasts. S1P induces osteoblast precursor recruitment and promotes mature cell survival. Wnt10b and BMP6 also were significantly increased in mature osteoclasts, whereas sclerostin levels decreased during differentiation. Stimulation of hMS cell nodule formation by osteoclast conditioned media was attenuated by the Wnt antagonist Dkk1, a BMP6-neutralizing antibody, and by a S1P antagonist. BMP6 antibodies and the S1P antagonist, but not Dkk1, reduced osteoclast conditioned media-induced hMS chemokinesis. In summary, our findings indicate that osteoclasts may recruit osteoprogenitors to the site of bone remodeling through SIP and BMP6 and stimulate bone formation through increased activation of Wnt/BMP pathways.
Racial Disparity in Breast Cancer and Functional Germ Line Mutation in Galectin-3 (rs4644): A Pilot Study
Balan, Vitaly, Nangia‐Makker, Pratima , Schwartz, Ann G. , Jung, Young Suk, Tait, Larry, Hogan, Victor, Raz, Tirza, Yang, Zeng Quan , Wu, Gen Sheng , Li, Huixiang , Abrams, Judith , Lingle, Wilma L., Lloyd, Ricardo V., Ethier, Stephen P. , Tainsky, Michael A. , Raz, Avraham, Wang, Yi , Guo, Yongjun , Couch, Fergus J.

Cancer Research | December 15, 2008 | Volume: 68 | Issue: 24 | Pages: 10045-10050

10.1158/0008-5472.can-08-3224 | PMID 19074869 Get It

Abstract For reasons largely unknown, Caucasian women are at a significantly higher risk of developing breast cancer than Asian women. Over a decade ago, mutations in BRCA1/2 were identified as genetic risk factors; however, the discovery of additional breast cancer genes and genes contributing to racial disparities are lacking. We report a functional germline mutation (polymorphism) in the galectin-3 gene at position 191 (rs4644) substituting proline with histidine (P64H), which results in susceptibility to matrix metalloproteinase cleavage and acquisition of resistance to drug-induced apoptosis. This substitution correlates with incidence of breast cancer and racial disparity. Genotype analysis of 338 Caucasian (194 disease free and 144 breast cancer patients) and 140 Asian (79 disease free and 61 breast cancer patients) women showed that the allele homozygous for H64 exists in disease free Caucasian and Asian women at a frequency of 12% and 5%, respectively, versus 37% and 82% in breast cancer patients. The data indicate that H/H allele is associated with increased breast cancer risk in both races. The data implicate galectin-3 H64 in breast cancer and explain, in part, the noted racial disparity, thus providing a novel target for diagnosis and treatment. [Cancer Res 2008;68(24):10045–50]
p53 Small-Molecule Inhibitor Enhances Temozolomide Cytotoxic Activity against Intracranial Glioblastoma Xenografts
Dinca, Eduard B., Lu, Kan , Pieper, Russell O., Prados, Michael D. , Haas‐Kogan, Daphne A. , VandenBerg, Scott R., James, C. David , Sarkaria, Jann N. , Berger, Mitchel S.

Cancer Research | December 15, 2008 | Volume: 68 | Issue: 24 | Pages: 10034-10039

10.1158/0008-5472.can-08-1687 | PMID 19074867 Get It

Abstract In this study, we investigated the precursor and active forms of a p53 small-molecule inhibitor for their effects on temozolomide (TMZ) antitumor activity against glioblastoma (GBM), using both in vitro and in vivo experimental approaches. Results from in vitro cell viability analysis showed that the cytotoxic activity of TMZ was substantially increased when p53 wild-type (p53wt) GBMs were cotreated with the active form of p53 inhibitor, and this heightened cytotoxic response was accompanied by increased poly(ADP-ribose) polymerase cleavage as well as elevated cellular phospho-H2AX. Analysis of the same series of GBMs, as intracranial xenografts in athymic mice, and administering corresponding p53 inhibitor precursor, which is converted to the active compound in vivo, yielded results consistent with the in vitro analyses: TMZ + p53 inhibitor precursor cotreatment of three distinct p53wt GBM xenografts resulted in significant enhancement of TMZ antitumor effect relative to treatment with TMZ alone, as indicated by serial bioluminescence monitoring as well as survival analysis (P < 0.001 for cotreatment survival benefit in each case). Mice receiving intracranial injection with p53null GBM showed similar survival benefit from TMZ treatment regardless of the presence or absence of p53 inhibitor precursor. In total, our results indicate that the p53 active and precursor inhibitor pair enhances TMZ cytotoxicity in vitro and in vivo, respectively, and do so in a p53-dependent manner. [Cancer Res 2008;68(24):10034–8]
Induction of Noxa Sensitizes Human Colorectal Cancer Cells Expressing Mcl-1 to the Small-Molecule Bcl-2/Bcl-xL Inhibitor, ABT-737
Huang, Shengbing, Okumura, Kenji , Sinicrope, Frank A.

Clinical Cancer Research | December 15, 2008 | Volume: 14 | Issue: 24 | Pages: 8132-8142

10.1158/1078-0432.ccr-08-1665 | PMID 19088028 Get It

Abstract Purpose: The intrinsic drug resistance of colorectal cancers is related in part to overexpression of prosurvival Bcl-2 family proteins. We determined the effects of ABT-737, a small-molecule inhibitor of Bcl-2/Bcl-xL but not Mcl-1, on apoptosis induction alone and in combination with CPT-11 and explored mechanisms underlying their cooperativity. Experimental Design: Human colorectal carcinoma cell lines (HCT116 wild-type and Bax-/-, HT-29, and RKO) were incubated with ABT-737 alone and combined with CPT-11 or bortezomib, and cell viability, caspase cleavage, and Annexin V labeling were measured. In drug-treated cell lines, protein-protein interactions were analyzed by immunoprecipitation. Lentiviral short hairpin RNA was used to knockdown Noxa expression. Results: ABT-737 induced apoptosis in a dose-dependent manner and its coadministration with the topoisomerase I inhibitor, CPT-11, resulted in a synergistic cytotoxic effect. Apoptosis induction by the drug combination was associated with enhanced caspase-8, caspase-9, and caspase-3 activation and poly(ADP-ribose) polymerase cleavage that were completely abrogated in Bax knockout cells. ABT-737 unsequestered the BH3-only protein Bim from its complex with Bcl-xL or Bcl-2 and disrupted the interaction of Bcl-xL with Bak. CPT-11 treatment up-regulated Noxa expression, as did bortezomib, and enhanced Noxa/Mcl-1 complexes. CPT-11 also disrupted the Mcl-1/Bak interaction. Knockdown of Noxa using short hairpin RNA lentiviral constructs was shown to significantly attenuate the cytotoxic effect of CPT-11 or bortezomib combined with ABT-737 and inhibited caspase-3 cleavage. Conclusions: Induction of Noxa by CPT-11 or bortezomib can sensitize colorectal cancer cells expressing Mcl-1 to ABT-737. Up-regulation of Noxa may therefore represent an important strategy to enhance the therapeutic efficacy of ABT-737 against colorectal cancer and other solid tumors.
Essential fatty acid profiling for routine nutritional assessment unmasks adrenoleukodystrophy in an infant with isovaleric acidaemia
Guerrero, Rubén Bonilla , Wolfe, Larry A., Payne, Nicole, Tortorelli, Silvia , Matern, Dietrich , Rinaldo, Piero, Gavrilov, Dimitar , Melan, Melissa A. , He, Miao , Steinberg, Steven J. , Raymond, Gerald V. , Vockley, Jerry , Gibson, K. Michael

Journal of Inherited Metabolic Disease | December 13, 2008 | Volume: 31 | Issue: S2 | Pages: 453-456

10.1007/s10545-008-1039-y | PMID 19089597 Get It

SummaryWe report a 16‐month‐old asymptomatic male with enzyme confirmed isovaleric acidaemia (IVA; isovaleryl‐CoA dehydrogenase deficiency; OMIM 243500) who, upon routine nutritional follow‐up, presented evidence of peroxisomal dysfunction. The newborn screen (2 days of life) revealed elevated C5‐carnitine (2.95 μmol/L; cutoff <0.09 μmol/L) and IVA was subsequently confirmed by metabolic profiling and in vitro enzymology. Plasma essential fatty acid (EFA) analysis, assessed to evaluate nutritional status during protein restriction and l‐carnitine supplementation, revealed elevated C26:0 (5.0 μmol/L; normal <1.3). Subsequently, metabolic profiling and molecular genetic analysis confirmed X‐linked adrenoleukodystrophy (XALD). Identification of co‐inherited XALD with IVA in this currently asymptomatic patient holds significant treatment ramifications for the proband prior to the onset of neurological sequelae, and critically important counselling implications for this family.
The Prognostic Value of Cardiopulmonary Exercise Testing in Idiopathic Pulmonary Fibrosis
Fell, Charlene D. , Liu, Lyrica Xiaohong, Motika, Caroline, Kazerooni, Ella A. , Gross, Barry H., Colby, Thomas V. , Murray, Susan , Toews, Galen B., Flaherty, Kevin R. , Motika, Caroline A., Travis, William D. , Martínez, Fernando J.

American Journal of Respiratory and Critical Care Medicine | December 12, 2008 | Volume: 179 | Issue: 5 | Pages: 402-407

10.1164/rccm.200802-241oc | PMID 19074597 Get It

Abstract Rationale Idiopathic pulmonary fibrosis (IPF) is characterized by progressive dyspnea, impaired gas exchange, and ultimate mortality. Objectives To test the hypothesis that maximal oxygen uptake during cardiopulmonary exercise testing at baseline and with short-term longitudinal measures would predict mortality in patients with idiopathic pulmonary fibrosis. Methods Data from 117 patients with IPF and longitudinal cardiopulmonary exercise tests were examined retrospectively. Survival was calculated from the date of the first cardiopulmonary exercise test. Measurements and Main Results Patients with baseline maximal oxygen uptake less than 8.3 ml/kg/min had an increased risk of death (n = 8; hazard ratio, 3.24; 95% confidence interval, 1.10–9.56; P = 0.03) after adjusting for age, gender, smoking status, baseline forced vital capacity, and baseline diffusion capacity for carbon monoxide. We were unable to define a unit change in maximal oxygen uptake that predicted survival in our cohort. Conclusions We conclude that a threshold maximal oxygen uptake of 8.3 ml/kg/min during cardiopulmonary exercise testing at baseline adds prognostic information for patients with IPF.
Effects of age and gender on the movement workspace of the trapeziometacarpal joint
Kuo, L-C, Cooney, W.P., An, K-N., Lai, K.Y., Wang, S-M, Su, Fong‐Chin , Kuo, Li‐Chieh , Kuo, L-C, Wang, S-M

Proceedings of the Institution of Mechanical Engineers, Part H: Journal of Engineering in Medicine | December 12, 2008 | Volume: 223 | Issue: 2 | Pages: 133-142

10.1243/09544119jeim489 | PMID 19278191 Get It

While researchers have suggested that joint mobility would probably be affected by age and gender, research findings often present discrepancies. Little research has been performed on the factors which effect mobility of the trapeziometacarpal (TMC) joint. The purpose of this study was to address the effects of age and gender on the ranges of motion of the normal TMC joint. Eighty normal subjects divided into four age groups participated in this study. The TMC joint motions were recorded using an electromagnetic tracking system. In order to achieve a maximal range of TMC joint motion which was defined as the maximal workspace, each subject was asked to perform actively maximal circumduction, flexion—extension, and abduction—adduction of the TMC joint. Numerical and statistical methods were used to compute the TMC workspace and to detect significant differences. A workspace-to-length ratio was determined as an index to examine the effects of the age and gender on the joint mobility. The results demonstrated that age and gender had significant influences on the TMC workspace among the groups studied. The understanding of TMC joint mobility under different age and gender conditions is achieved through this study. The findings can be used to report clinical measures in the determination of the extent of impairment of osteoarthritis as well as the outcomes between pre- and post-surgical (or non-surgical) interventions.